Vectura Likes Risk Proposition Of New U.S. Partnership For Generic Lung Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
British biotech partners with unnamed multinational pharma to develop VR315, thought by many to be a generic version of GSK's Advair, in the U.S.
You may also be interested in...
Vectura Pursues U.S. Partner For Inhaled Respiratory Therapy - A Generic Advair?
Vectura could launch a competitor to Advair in 2011 in Europe, while looking for a U.S. partner.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.